AU2019301887A1 - Alkoxy pyrazoles as soluble guanylate cyclase activators - Google Patents
Alkoxy pyrazoles as soluble guanylate cyclase activators Download PDFInfo
- Publication number
- AU2019301887A1 AU2019301887A1 AU2019301887A AU2019301887A AU2019301887A1 AU 2019301887 A1 AU2019301887 A1 AU 2019301887A1 AU 2019301887 A AU2019301887 A AU 2019301887A AU 2019301887 A AU2019301887 A AU 2019301887A AU 2019301887 A1 AU2019301887 A1 AU 2019301887A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- heterocyclyl
- compound
- group
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696887P | 2018-07-12 | 2018-07-12 | |
| US62/696,887 | 2018-07-12 | ||
| PCT/EP2019/068448 WO2020011804A1 (en) | 2018-07-12 | 2019-07-09 | Alkoxy pyrazoles as soluble guanylate cyclase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019301887A1 true AU2019301887A1 (en) | 2021-01-07 |
Family
ID=67314737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019301887A Abandoned AU2019301887A1 (en) | 2018-07-12 | 2019-07-09 | Alkoxy pyrazoles as soluble guanylate cyclase activators |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11690848B2 (https=) |
| EP (1) | EP3820470B1 (https=) |
| JP (2) | JP2021530488A (https=) |
| KR (1) | KR20210032443A (https=) |
| CN (1) | CN112384214A (https=) |
| AU (1) | AU2019301887A1 (https=) |
| BR (1) | BR112020025670A2 (https=) |
| CA (1) | CA3103727A1 (https=) |
| CL (1) | CL2021000023A1 (https=) |
| EA (1) | EA202190193A1 (https=) |
| MA (1) | MA53118A (https=) |
| MX (1) | MX2021000405A (https=) |
| PH (1) | PH12021550075A1 (https=) |
| WO (1) | WO2020011804A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118900690A (zh) * | 2022-03-21 | 2024-11-05 | 勃林格殷格翰国际有限公司 | 用于治疗门脉高压的可溶性鸟苷酸环化酶活化剂 |
| WO2024097316A1 (en) | 2022-11-04 | 2024-05-10 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators for treating systemic sclerosis |
| US20240199590A1 (en) | 2022-12-09 | 2024-06-20 | Boehringer Ingelheim International Gmbh | Solid forms of a sgc activator |
| WO2025036839A1 (en) * | 2023-08-16 | 2025-02-20 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators for treating clinically significant portal hypertension and decompensated cirrhosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2748798T3 (es) | 2012-09-07 | 2020-03-18 | Boehringer Ingelheim Int | Alcoxi pirazoles como activadores de la guanilato ciclasa soluble |
| BR112018015718A2 (pt) * | 2016-02-01 | 2019-01-08 | Ironwood Pharmaceuticals Inc | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) |
| US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
-
2019
- 2019-07-09 EP EP19740509.5A patent/EP3820470B1/en active Active
- 2019-07-09 EA EA202190193A patent/EA202190193A1/ru unknown
- 2019-07-09 KR KR1020217004281A patent/KR20210032443A/ko not_active Ceased
- 2019-07-09 CN CN201980045881.XA patent/CN112384214A/zh active Pending
- 2019-07-09 MX MX2021000405A patent/MX2021000405A/es unknown
- 2019-07-09 WO PCT/EP2019/068448 patent/WO2020011804A1/en not_active Ceased
- 2019-07-09 CA CA3103727A patent/CA3103727A1/en active Pending
- 2019-07-09 US US17/258,759 patent/US11690848B2/en active Active
- 2019-07-09 JP JP2021500613A patent/JP2021530488A/ja active Pending
- 2019-07-09 AU AU2019301887A patent/AU2019301887A1/en not_active Abandoned
- 2019-07-09 MA MA053118A patent/MA53118A/fr unknown
- 2019-07-09 BR BR112020025670-6A patent/BR112020025670A2/pt not_active IP Right Cessation
-
2021
- 2021-01-06 CL CL2021000023A patent/CL2021000023A1/es unknown
- 2021-01-12 PH PH12021550075A patent/PH12021550075A1/en unknown
-
2024
- 2024-03-27 JP JP2024052193A patent/JP2024095711A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021000405A (es) | 2021-03-25 |
| CA3103727A1 (en) | 2020-01-16 |
| MA53118A (fr) | 2021-05-19 |
| KR20210032443A (ko) | 2021-03-24 |
| WO2020011804A1 (en) | 2020-01-16 |
| EA202190193A1 (ru) | 2021-06-16 |
| JP2021530488A (ja) | 2021-11-11 |
| JP2024095711A (ja) | 2024-07-10 |
| US20210121473A1 (en) | 2021-04-29 |
| US11690848B2 (en) | 2023-07-04 |
| BR112020025670A2 (pt) | 2021-03-16 |
| CL2021000023A1 (es) | 2021-06-11 |
| CN112384214A (zh) | 2021-02-19 |
| PH12021550075A1 (en) | 2021-09-20 |
| EP3820470A1 (en) | 2021-05-19 |
| EP3820470B1 (en) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11690848B2 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| JP6180420B2 (ja) | 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体 | |
| TWI852999B (zh) | 治療脂肪性肝病及/或脂肪性肝炎的方法 | |
| AU2016232191A1 (en) | NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat | |
| CA3166387A1 (en) | Methods of treating coronavirus | |
| JP2012508205A (ja) | Ｄｈｏｄｈインヒビター及びメトトレキセートを含んで成る、自己免疫疾患を処理するための組合せ治療 | |
| JP2026053473A (ja) | 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸 | |
| JP2022552975A (ja) | 関節リウマチを予防及び／又は治療するためのニコチンアミドモノヌクレオチド（ｎｍｎ）の使用、並びに対応する組成物 | |
| US20230293513A1 (en) | Soluble guanylate cyclase activators for treating portal hypertension | |
| WO2024211708A1 (en) | Tyk2 inhibitors for treatment of glaucoma | |
| EA042973B1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| JP5559696B2 (ja) | 糖尿病性腎症の治療剤 | |
| US20240325336A1 (en) | Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis | |
| US11413273B2 (en) | Prophylactic or therapeutic agent for pulmonary hypertension comprising unsaturated 5-membered heterocycle-containing compound | |
| JPS625923A (ja) | アレルギ−性疾患治療剤 | |
| HK40054971A (en) | Method for treating fatty liver disease and/or steatohepatitis | |
| HK1242243A1 (en) | Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat | |
| HK1242243B (en) | Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |